ZNF772: A Potential Drug Target and Biomarker (G400720)
ZNF772: A Potential Drug Target and Biomarker
Zinc finger proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in cellular signaling and gene regulation. ZNF772, a specific ZFP, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The ZNF772 Protein
ZNF772 is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is a key regulator of cell proliferation, differentiation, and survival. ZNF772 functions by forming a complex with other transcription factors, such as NF-kappa-B and p53, to regulate gene expression and ensure the stability of chromatin.
ZNF772 has been shown to play a key role in the regulation of various cellular processes, including cell adhesion, migration, and the development of cancer. It has been shown to promote the growth and survival of cancer cells, and it has been used as a potential drug target in various clinical trials.
Potential Drug Target
The potential drug target for ZNF772 is its role in the regulation of cell proliferation and survival. Drugs that target ZNF772 have been shown to inhibit its activity, leading to the inhibition of cell proliferation and the inhibition of the formation of new blood vessels. This results in the inhibition of tumor growth and the inhibition of the spread of cancer.
In addition, ZNF772 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. The regulation of angiogenesis is critical for the development and progression of cancer, and targeting ZNF772 has been shown to be an effective way to treat various types of cancer.
Biomarker
ZNF772 has also been identified as a potential biomarker for various diseases, including cancer. The levels of ZNF772 have been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that ZNF772 may be a useful biomarker for the diagnosis and monitoring of cancer.
Monoclonal antibodies (Mabs), which are laboratory-produced molecules that recognize a specific protein, have been developed to target ZNF772. These Mabs have been shown to be effective in inhibiting the activity of ZNF772 and have been used in various clinical trials to treat various types of cancer.
Conclusion
ZNF772 is a protein that has been shown to play a crucial role in the regulation of various cellular processes, including cell proliferation and survival. Its potential drug target status and biomarker potential make it an attractive target for the development of new treatments for various types of cancer. Further research is needed to fully understand the role of ZNF772 in the regulation of cellular processes and its potential as a drug target and biomarker.
Protein Name: Zinc Finger Protein 772
Functions: May be involved in transcriptional regulation
More Common Targets
ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843 | ZNF844 | ZNF845 | ZNF846 | ZNF85 | ZNF850 | ZNF852 | ZNF853 | ZNF860 | ZNF862 | ZNF865 | ZNF875 | ZNF876P | ZNF878 | ZNF879 | ZNF880 | ZNF883 | ZNF887P | ZNF888 | ZNF890P | ZNF891 | ZNF90 | ZNF91 | ZNF92 | ZNF93 | ZNF962P | ZNF98 | ZNF99 | ZNFX1 | ZNG1A | ZNG1B | ZNG1C | ZNG1E | ZNG1F | ZNHIT1 | ZNHIT2 | ZNHIT3 | ZNHIT6 | ZNRD2 | ZNRD2-DT | ZNRF1 | ZNRF2
